681 results about "Lyase" patented technology

Enhanced removal and/or control of adhesives or sticky materials, “stickies”, from recovered paper stock or virgin pulp fibers is achieved using a combination of enzyme treatment with adsorbents and/or absorbents. Pulp stock to be treated is typically obtained from old magazines, newspapers, household waste, but may include corrugated boxes and office waste. Virgin pulps may include mechanical, chemical, or semi-chemical pulps. Enzymes typically include hydrolases such as cellulases, hemicellulases, pectinases, amylases, and lipases such as esterases, lyases such as pectate lyases, and oxidoreductases. Adsorbents include activated bentonite, microparticles, talc, clay and modified silica. Absorbents typically include water soluble polymers, dispersants, coagulatants and agglomerants.

A composition and method for treating bacterial infections by the use of an effective amount of at least one lytic specific for the bacteria causing specific. The lytic enzyme is genetically coded for by a bacteriophage which may be specific for said bacteria. The enzyme may be at least one lytic protein or peptides in a natural or modified form.

A new class of nucleic acid substrates for AP endonucleases and members of the glycosylase/lyase family of enzymes is described. Representatives of each family, the enzymes Nfo and fpg, respectively, cleave nucleic acid backbones at positions in which a base has been replaced by a linker to which a variety of label moieties may be attached. The use of these synthetic substrates embedded within oligonucleotides is of utility in a number of applications.

Methods for treating certain cancers in patients, such as mammals, using certain 17α-hydroxylase/C_17,20-lyase inhibitors are discussed herein. More particularly, methods for treating cancers comprising administering a 17α-hydroxylase/C_17,20-lyase inhibitor, such as abiraterone acetate (i.e. 3β-acetoxy-17-(3-pyridyl) androsta-5,16-diene) and metabolites thereof are described. In addition, methods for treating cancers that are refractory to hormone therapy or that are refractory to chemotherapy are also discussed. Finally novel dosing regimens and novel uses of the compounds discussed herein are disclosed.

The invention belongs to the field of cosmetics, and particularly relates to a composition containing bifida ferment lysate and a preparation method and application of the composition to the cosmetics. The composition includes a bifida ferment lysate composition, a peptide composition and a rice extract, and the composition is prepared from the following components in parts by mass: 1-40 parts ofthe bifida ferment lysate, 1-20 parts of the peptide composition, and 1-20 parts of the rice extract, and the composition further includes 1-20 parts of a moisturizing composition, and the bifida ferment lysate composition includes bifida freeze-dried powder, and a bifida freeze-dried powder lyase solution. The composition containing the bifida ferment lysate has the beneficial effects that a formula is reasonably set, functions are various, wrinkles can be significantly reduced, the pigment content is reduced, skin glossiness is increased, the skin color is brightened, skin elasticity is increased, the skin barrier is repaired, the water loss is reduced, the composition has no stimulation to the skin, and at the same time, the composition has the functions of preventing skin aging and keeping moisture for a long time, and makes the skin obtain a healthy and natural bright white state.

The present invention provides several methods for biological production of para-hydroxycinnamic acid (PHCA). The invention is also directed to the discovery of new fungi and bacteria that possess the ability to convert cinnamate to PHCA. The invention relates to developing of a new biocatalyst for conversion of glucose to PHCA by incorporation of the wild type PAL from the yeast Rhodotorula glutinis into E. coli underlining the ability of the wildtype PAL to convert tyrosine to PHCA. The invention is also directed to developing a new biocatalyst for conversion of glucose to PHCA by incorporation of the wildtype PAL from the yeast Rhodotorula glutinis plus the plant cytochrome P-450 and the cytochrome P-450 reductase into E. coli. In yet another embodiment, the present invention provides for the developing of a new biocatalyst through mutagenesis of the wild type yeast PAL which possesses enhanced tyrosine ammonia-lyase (TAL) activity.

Conversion in vitro of X-Gly to X-alpha-hydroxy-Gly or X—NH₂ (X being a peptide or any other compound having a carbonyl group capable of forming a covalent bond with glycine) is accomplished enzymatically in the presence of keto acids, or salts or esters thereof, to provide a good yield without the necessity of catalase or similar enzymatic reaction enhancers. Peptidylglycine α-amidating monooxygenase (PAM) is a preferred enzyme for catalyzing the conversion. Alternatively, peptidylglycine α-hydroxylating monooxygenase (PHM) is utilized to convert X-Gly to X-alpha-hydroxy-Gly which may be recovered, or optionally may be simultaneously or sequentially converted to an amide by either a Lewis base or action of the enzyme peptidyl α-hydroxyglycine α-amidating lyase (PAL). Both PHM and PAL are functional domains of PAM.

The invention discloses an alpha-ketoglutarate producing yeast engineering strain and a construction method thereof, which belong to the field of genetic engineering. In the method, a molecular approach is adopted, and the yeast engineering strain Y.lipolytica ACL with improved ATP-citrate lyase activity is obtained by over-expressing an ATP-ATP-citrate lyase ACL coding gene from a mouse into a strain Yarrowia lipolytica WSH-Z06 for producing alpha-ketoglutarate by a fermentation method. Compared with a parent strain, the genetic engineering strain provided by the invention can intracellularly accumulate acetyl coenzyme A with the dry cell weight (DCW) of 0.89 mM/g by adopting glycerol as the unique carbon source so as to achieve the ACL activity of 3.56 U/mg protein improved by 7.5 times, achieve the alpha-ketoglutarat yield of 45.3 g/L which is 1.29 times that of parent protein and reduce the pyruvic acid yield to 17.2 g/L which is 68.8 percent of that of the parent strain, and has vast application prospect.

Methods for providing transgenic plants and parts hereof that, relative to the wild type state, is modified in a complex cell wall polysaccharide structure including pectins and hemicelluloses, the modification being in the overall glycosidic linkage pattern or the monosaccharide profile, comprising transforming a plant cell with a nucleotide sequence that causes an altered production of a complex cell wall polysaccharide-modifying enzyme such as endo-rhamnogalacturonan hydrolase, an endo-rhamnogalacturonan lyase, an endo-galactanase, an endo-arabinanase, an arabinofuranosidase, a galactosidase such as a beta-galactosidase, a xylosidase and an exo-galacturosidase. The modification can occur in vivo or post harvest, in which latter case the modifying enzyme is separated in the growing plant from its substrate, e.g. by targeting the enzyme to the Golgi, the endoplasmic reticulum or a vacuole, or is in a form that is inactive in the plant. After harvest the enzyme is brought into contact with its substrate or it is activated to provide the desired post harvest modification of the cell wall polysaccharide. The transgenic plant materials have improved functionalities and are useful in food and feed manufacturing and as pharmaceutically or medically active substances.

The invention discloses a lyase for killing staphylococcus and an application of the lyase and also discloses an amino acid sequence and an encoding gene sequence of the lyase. A recombined lyase constructed by using the disclosed encoding gene can realize soluble expression in Escherichia coli BL21 (DE3); the lyase can be used for efficiently killing various types of staphylococcus including clinically-separated methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA) in vitro and can also be used as an antibiotic for treating staphylococcus infection in vivo; and the disclosed lyase can also be used for rapidly cracking the cell wall of the staphylococcus and releasing substances in cells, such as adenosine triphosphate (ATP), DNA (Deoxyribonucleic Acid) and the like, and various detections on the staphylococcus can be realized through detecting released substances.

The invention relates to a Vibrio FC509 strain and a culturing method and application thereof. The Vibrio FC509 strain is collected in the China General Microbiological Culture Collection Center (CGMCC) on 12, March, 2014, with a collection number of CGMCC NO.8913 and an address of Institute of Microbiology Chinese Academy of Sciences NO.1 West Beichen Road, Chaoyang District, Beijing. The Vibrio sp. FC509 strain obtained by first-time separation is capable of preparing glycosaminoglycan lyase which has a specific activity of 110,000U/mg to hyaluronic acid and specific activity of 45,000U/mg to chondroitin sulfate; enzyme activity is tens to hundreds times that of the known commercialized glycosaminoglycan lyase, can be applied to fields such as medicines, cosmetics and the like, and is wide in application prospect.